XORTX Therapeutics (XORTX Therapeutics) Equity-to-Asset

: 0.92 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. XORTX Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $6.09 Mil. XORTX Therapeutics's Total Assets for the quarter that ended in Sep. 2023 was $6.64 Mil.

The historical rank and industry rank for XORTX Therapeutics's Equity-to-Asset or its related term are showing as below:

XRTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.54 Med: 0.67 Max: 0.98
Current: 0.92

During the past 8 years, the highest Equity to Asset Ratio of XORTX Therapeutics was 0.98. The lowest was -0.54. And the median was 0.67.

XRTX's Equity-to-Asset is ranked better than
89.83% of 1564 companies
in the Biotechnology industry
Industry Median: 0.66 vs XRTX: 0.92

XORTX Therapeutics Equity-to-Asset Historical Data

The historical data trend for XORTX Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Equity-to-Asset

Get a 7-Day Free Trial

0.25

-0.19

0.55

0.76

0.57

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Equity-to-Asset	Get a 7-Day Free Trial															0.72	0.57	0.94	0.95	0.92

Competitive Comparison

For the Biotechnology subindustry, XORTX Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Equity-to-Asset falls into.

XORTX Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

XORTX Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	6.975	/	12.344
	=

XORTX Therapeutics's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	6.086	/	6.64
	=

XORTX Therapeutics (NAS:XRTX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

XORTX Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.